Holy Stone Healthcare - Certified “Biotech and New Pharmaceutical company"
16, Aug 2011
Holy Stone Enterprise Co., Ltd. (Holy Stone) (TWSE: 3026), a passive component manufacturer and an IC distributor, today announced Holy Stone Healthcare Co., Ltd. is certified as a “Biotech and New Pharmaceutical company”.
According to the second section in Article III of “Biotech and New Pharmaceutical Development Act” and its relevant provisions, Holy Stone Healthcare Co., Ltd., Holy Stone’s reinvested company, has received certification from the Ministry of Economic Affairs as a Biotech and New Pharmaceutical company.
Established in 2001, Holy Stone Healthcare Co., Ltd. (Holy Stone Healthcare) is committed to developing medicinal and biotech products having great potentials. Currently, Holy Stone Healthcare is developing serial new drugs for gastrointestinal disease, and filling several patents.
Holy Stone Healthcare uses its HDD drug delivery technology platform to develop new drugs with better efficacy and fewer side effects against gastrointestinal diseases. IBD98 is the first drug developed by using such technology platform to treat Inflammatory Bowel Disease (IBD). As a new type of treatment with greater safety profile compared to current IBD drugs, the drug increases the patients’ safety and convenience. IBD is an idiosyncratic inflammatory disease, an autoimmune disease that may be caused by intestinal allergens. IBD includes ulcerative colitis and Crohn's disease. General symptoms are ulcerating, swelling, and bleeding of intestinal mucosal leading to loss of body fluids and electrolytes.
The formulation development of IBD98 has been completed, and the animal study is ongoing. Moreover, the global patent is filling. Holy Stone Healthcare has two biotech patents (SportsVis and Renehavis) granted and both products are marketed by its European marketing team.